REMARKS

Reconsideration of this application is requested. Claims 1-22 are in the case.

I. ABSTRACT

The typographical errors in the Abstract have been noted. A new Abstract of the Disclosure is presented herewith in which the typographical errors have been corrected. The Examiner is thanked for drawing these errors to the attention of the undersigned.

II. THE 35 U.S.C. § 112, SECOND PARAGRAPH, REJECTION

Claims 1-20 stand rejected under 35 U.S.C. § 112, second paragraph, as allegedly indefinite for the reasons detailed on pages 3 and 4 of the Action. In response, the claims have been amended to deal with the Examiner's points. The following comments are offered.

Claim 1 has been rejected as allegedly indefinite in view of the period following "method". In response the period has been deleted.

Claims 1, 14, 19 and 20 stand rejected in view of the expression "preferably" and because claims 19 and 20 do not further limit claim 14 for the reasons stated at the top of page 4 of the Action. In response, the preferred features have been canceled from claims 1 and 14. Claim 19 has been further amended to replace "blood plasma fraction" with "solution", and claim 20 has been amended to delete "to obtain said fibrinogen enriched preparation". In

addition, new dependent claims 21 and 22 are presented for consideration by the Examiner. No new matter is entered.

Withdrawal of the outstanding 35 U.S.C. § 112, second paragraph, rejection is now believed to be in order. Such action is respectfully requested.

Allowance of the application is awaited.

Attached hereto is a marked-up version of the changes made to the specification and claim(s) by the current amendment. The attached page(s) is captioned **"Version With Markings To Show Changes Made."**

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: _____
Leonard C. Mitchard
Reg. No. 29,009

LCM:lfm
1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE CLAIMS

1. (Twice Amended) A method of obtaining a fibrinogen enriched preparation, the method[.] comprising the following steps:-

(i) adding an effective amount of a sulphated polysaccharide (SPS) to a fibrinogen containing solution to form a fibrinogen containing precipitate; and

(ii) extracting fibrinogen from the fibrinogen containing precipitate from step (i) with a solution containing at least 0.1M[, and preferably at least 0.2M,] salt to obtain a fibrinogen enriched preparation.

14. (Twice Amended) A method of obtaining a preparation enriched for fibronectin or Factor VIII, the method comprising the following steps:-

(i) adding an effective amount of a sulphated polysaccharide (SPS) to a fibrinogen containing blood plasma fraction [preferably cryoprecipitate] to form a fibrinogen containing precipitate;

(ii) extracting from the fibrinogen containing precipitate from step (i) with a solution containing at least 0.1M[, and preferably at least 0.2M,] salt to obtain a fibrinogen enriched preparation;

(iii) extracting fibronectin or Factor VIII from the fibrinogen enriched preparation obtained in step (ii).

19. (Amended) A method as claimed in claim 14 in which, in step (i), the fibrinogen containing [blood plasma fraction] solution is a cryoprecipitate.

20. (Amended) A method as claimed in claim 14 in which, in step (ii), the solution contains at least 0.2M salt [to obtain said fibrinogen enriched preparation].

New claims 21-22 have been added.